The work, led by Azam Chahardoli of the Department of Biology at Razi University in Kermanshah, Iran, together with Ali Mostafaei of the Medical Biology Research Center at Kermanshah University of Medical Sciences, tackles one of the central challenges in nanomedicine: how to produce metallic nanoparticles that are stable, biocompatible, and functional without resorting to toxic synthetic reagents. Gold nanoparticles have long been celebrated for their chemical inertness, ease of synthesis, and utility in drug delivery, imaging, and photothermal therapy. Yet the capping and reducing agents traditionally used to keep them from clumping—citrate, thiols, or synthetic polymers—can introduce their own biological liabilities. Quercetin offers an elegant solution. As a polyphenolic flavonoid, it possesses multiple hydroxyl groups capable of reducing gold ions to metallic gold while simultaneously adsorbing onto the particle surface, acting as a built-in stabilizer and, in principle, a therapeutic payload in its own right.

The synthesis itself is deceptively simple in concept. When quercetin is introduced to a gold salt solution, the flavonoid’s phenolic groups donate electrons to gold ions, reducing them to gold atoms that nucleate and grow into nanoparticles. The quercetin molecules then coat the emerging particles, capping their surfaces and preventing aggregation through steric and electrostatic repulsion. The resulting quercetin-stabilized gold nanoparticles, or QU-GNPs, were characterized with a battery of analytical techniques that together paint a detailed portrait of their structure and behavior.

Ultraviolet-visible spectroscopy provided the first signature of success. The formation of gold nanoparticles is typically heralded by surface plasmon resonance—the collective oscillation of conduction electrons at the particle surface when struck by light—and the QU-GNPs displayed a maximum absorption peak at 532 nanometers, squarely in the range expected for well-dispersed spherical gold nanoparticles. X-ray diffraction confirmed a crystalline gold structure, with the diffraction pattern consistent with the face-centered cubic lattice of metallic gold. Field emission scanning electron microscopy revealed predominantly spherical particles with an average diameter of 33.1 plus or minus 9 nanometers, while transmission electron microscopy, which probes the particle core with higher resolution, determined a smaller average diameter of 21.93 nanometers. The discrepancy between the two measurements is telling: the organic quercetin shell adds thickness around the electron-dense gold core, and each technique weights that architecture differently.

Dynamic light scattering measurements yielded a zeta potential of negative 26.9 millivolts, a value comfortably within the range generally associated with colloidal stability. Particles with zeta potentials of this magnitude repel one another electrostatically, resisting the aggregation that would otherwise compromise their performance in biological fluids. Energy-dispersive X-ray spectroscopy and elemental mapping added the final chemical confirmation, identifying gold, carbon, and oxygen as the primary constituent elements. The presence of carbon and oxygen—elements absent from the gold salt itself—unequivocally demonstrated that quercetin moieties had successfully functionalized the nanoparticle surfaces, creating the organic-inorganic hybrid interface that underpins the material’s biological behavior.

With the material’s structure established, the team turned to its biological profile, and the results are remarkable in their breadth. Antioxidant activity was assessed using the DPPH assay, a standard test in which a stable free radical changes color as it is neutralized by antioxidants. The QU-GNPs scavenged 81.7 percent of DPPH radicals at a concentration of 600 micrograms per milliliter, an effect attributable to the hydrogen-donating capacity of the quercetin shell, whose phenolic hydroxyl groups quench radical species and interrupt oxidative chain reactions. Because oxidative stress is implicated in inflammation, aging, and cancer progression, this radical-scavenging capacity provides a mechanistic foundation for the compound’s broader therapeutic claims.

The blood-compatibility studies are particularly noteworthy, since many nanoparticles fail at precisely this hurdle. When human red blood cells were incubated with QU-GNPs at 800 micrograms per milliliter, hemolysis—the rupture of red cell membranes and release of hemoglobin—was only 1.6 percent, well below the 5 percent threshold conventionally considered non-hemolytic. But the nanoparticles did more than simply avoid damaging blood cells. At 100 micrograms per milliliter, they protected the integrity of the red blood cell membrane by 95.1 percent in the face of a hypotonic challenge, suggesting a membrane-stabilizing effect reminiscent of the way classical anti-inflammatory drugs protect lysosomal membranes. This dual behavior—harmless to healthy cells yet actively protective—is a rare and valuable combination.

The anti-inflammatory potential was further probed using a protein denaturation assay with bovine serum albumin. Protein denaturation is a well-established in vitro model for inflammation, as the denatured proteins generated at sites of tissue injury are thought to trigger autoimmune and inflammatory cascades. Diclofenac sodium, a widely prescribed non-steroidal anti-inflammatory drug, served as the benchmark. At 400 micrograms per milliliter, the QU-GNPs blocked protein denaturation by 90.5 percent, a figure that places the nano-compound in the same performance territory as clinical anti-inflammatory agents and underscores the pharmacological punch of the quercetin coating once displayed on a nanoparticle surface.

Cancer-cell testing delivered perhaps the most clinically tantalizing results. Using the MTT assay, which measures metabolic activity as a proxy for cell viability, the researchers evaluated the nanoparticles against MCF-7 cells, a widely used human breast cancer cell line, alongside normal fibroblast cells as a healthy-tissue control. The QU-GNPs exhibited a significant cytotoxic effect against the MCF-7 cells, with an inhibitory concentration of 293.6 micrograms per milliliter, while showing no toxic potential whatsoever toward normal fibroblasts. This selectivity—damaging cancer cells while leaving healthy cells untouched—is the holy grail of anticancer therapy and one of the most persistent challenges in chemotherapy. The flavonoid coating may contribute to this selectivity, as quercetin is known to modulate signaling pathways that are dysregulated in cancer cells, while the nanoparticle platform may enhance cellular uptake and localized delivery of the bioactive molecules.

Antibacterial activity rounded out the therapeutic panel. Although the nanoparticle platform was formulated with complementary medicine applications in mind rather than as a conventional antibiotic, the QU-GNPs displayed high antibacterial activity in the assays performed. Multiple mechanisms are likely at play: gold nanoparticles are known to physically interact with bacterial membranes, disrupting their integrity, while the quercetin coating contributes its own well-documented antimicrobial pharmacology, including inhibition of essential bacterial enzymes and interference with quorum sensing. In an era of rising antimicrobial resistance, any new antibacterial platform—particularly one derived from food-based biomolecules—warrants close attention.

Taken together, the findings position quercetin-stabilized gold nanoparticles as what the authors call a novel bio-safe bio/nano-compound with genuine bio-therapeutic potential. The concept is compelling precisely because of its economy: a single plant-derived molecule performs triple duty as reducing agent, stabilizer, and therapeutic cargo, eliminating the need for synthetic capping agents and embedding pharmacological activity directly into the nanoparticle architecture. The particle size, falling in the range where cellular uptake and biodistribution are favorable, and the strongly negative zeta potential, predicting colloidal stability in physiological environments, add engineering credibility to the biological promise.

The authors are careful to frame the work appropriately. All results to date come from in vitro assays—test-tube experiments with purified radicals, isolated red blood cells, albumin solutions, and cultured cells—and the pathway from such experiments to clinical therapies runs through extensive in vivo investigation. Pharmacokinetics, biodistribution, long-term toxicity, immune response, and efficacy in living organisms all remain to be established. The hemolysis experiments did involve human blood samples obtained from healthy volunteers with informed consent under approval from the Ethical Committee of Kermanshah University of Medical Sciences, lending clinical grounding to the biocompatibility data, but the leap from cell culture to patient remains substantial.

Nevertheless, the study stands as a vivid example of how green nanotechnology and complementary medicine can inform one another. Quercetin has been a staple of dietary supplement research for decades, celebrated for its antioxidant and anti-inflammatory properties but hampered by poor solubility and low bioavailability. Anchoring it to gold nanoparticles could, in principle, circumvent some of these limitations while adding the intrinsic capabilities of a nanoscale platform. If future in vivo studies bear out the promise suggested by these in vitro results, the humble flavonoid that gives red onions and apples their pigment may find itself at the center of a new generation of multi-functional nanomedicines—antioxidant, anti-inflammatory, anticancer, and antibacterial all at once, and built from one of nature’s most familiar molecules.

The experimental agent, called Pro-LYTAC, belongs to a class of compounds known as lysosome-targeting chimeras, or LYTACs. These molecules are designed to eliminate selected proteins from the surface of cells rather than merely block their activity. A LYTAC typically combines a targeting component that recognizes a cell-surface protein with a ligand capable of engaging the cell’s lysosomal trafficking machinery. Once the complex is internalized, the lysosome—an organelle filled with enzymes that digest proteins and other cellular material—breaks down the targeted protein. This approach is potentially powerful because it can remove disease-promoting proteins that are difficult to inhibit with conventional small-molecule drugs.

The researchers led by Peng Shi and Mohan Chen sought to make this protein-degradation technology more selective by placing it behind a molecular gate. Their Pro-LYTAC is activated by glutathione, a small antioxidant peptide present in cells throughout the body but found at elevated concentrations in many tumors. Glutathione helps maintain the reducing environment inside cells and participates in the detoxification of reactive chemical compounds. By incorporating a glutathione-responsive chemical “cage” into the therapeutic design, the team aimed to prevent the active LYTAC structure from functioning until it encountered the biochemical conditions associated with malignant tissue. In principle, the inactive form can circulate without efficiently binding its target or engaging lysosomal uptake pathways, while the tumor-associated glutathione environment removes the protective lock.

This design transforms a feature of tumor biology into a molecular switch. Cancer cells frequently exhibit altered redox metabolism, increased antioxidant capacity and distinctive concentrations of intracellular metabolites. These differences are not universal across every tumor type, but they can provide chemical signals that are less pronounced in healthy tissues. In the Pro-LYTAC strategy, glutathione serves as the trigger that converts a relatively inert conjugate into a protein-degrading agent. The researchers constructed the therapeutic as a caged glycan-antibody conjugate, linking an antibody-based recognition element with a glycan component that can direct the complex toward lysosomal clearance. The cage is intended to reduce activity before activation, thereby limiting exposure of healthy organs to the fully functional degrader.

After the molecular lock is removed, Pro-LYTAC targets a protein that cancer cells use to avoid immune recognition. Many tumors survive in the body not only because they divide uncontrollably but also because they actively suppress or evade immune attack. Surface proteins involved in immune checkpoint signaling can function as protective shields, transmitting signals that prevent immune cells from efficiently identifying malignant cells as dangerous. By directing one of these immune-evasion proteins to the lysosome, Pro-LYTAC causes its physical removal from the cancer-cell surface. The result is not simply temporary inhibition of a protein’s activity; it is degradation of the protein itself, potentially producing a more sustained change in the cell’s interaction with the immune system.

The researchers evaluated the therapeutic in mouse models of triple-negative breast cancer, an aggressive disease subtype that lacks three commonly exploited molecular targets and therefore remains difficult to treat. During the two-week study, animals receiving Pro-LYTAC showed stronger tumor suppression than control animals treated with saline. The findings indicate that the compound was able to reach tumors, become activated under tumor-associated conditions and engage the intended protein-degradation pathway. Removing the immune-evasion shield is expected to make tumor cells more visible to immune defenses, allowing immune cells to recognize and attack them more effectively. The observed tumor reduction therefore reflects both the direct molecular action of the degrader and the possibility of a secondary antitumor immune response.

The distribution of the compound in the animals provided another important result. Pro-LYTAC was concentrated in tumor tissue, while only small quantities were detected in the liver. The liver is a major site of drug metabolism and clearance, and many therapeutic molecules accumulate there even when the liver is not the intended target. Excessive hepatic exposure can contribute to toxicity and may restrict the dose that can safely be administered. The researchers propose that the locked state of Pro-LYTAC outside the tumor reduces its interactions with healthy tissues and limits the formation of active species in the liver. This could lower the risk of adverse exposure, although detailed toxicology, long-term safety testing and studies in additional animal models will be required before any conclusions about clinical safety can be drawn.

The work also highlights a broader challenge in targeted protein degradation: reaching the right cells is only part of the problem. A degrader may be highly selective for a protein yet still cause toxicity if it remains active while circulating through the body. Conditional activation offers a second layer of control, combining molecular recognition with a biochemical trigger. In the case of Pro-LYTAC, the antibody and glycan components provide the framework for recognition and lysosomal delivery, while the glutathione-sensitive cage is intended to control when that framework becomes operational. Such “prodrug” architectures could eventually be adapted to other tumor-associated signals, including unusual enzyme activity, acidity, oxygen levels or reactive metabolites.

The findings remain an early demonstration in mice rather than evidence of a ready-to-use cancer medicine. Tumors in human patients are chemically and genetically diverse, and glutathione concentrations may vary between tumor types, treatment histories and individual patients. Researchers will need to determine how reliably the cage is removed in human tumors, whether enough active compound reaches malignant cells, how long the degraded protein remains suppressed and whether the immune response can be sustained. They must also assess the possibility of premature activation, immune reactions against the antibody or glycan components, and toxicity caused by unintended protein degradation. Nevertheless, the study presents a compelling route toward safer LYTAC therapy by using the tumor’s own biochemical environment to control drug activity. If the approach can be translated beyond animal models, it may help transform targeted protein degradation from a powerful but potentially broad-acting technology into a more precise weapon against cancer.

Subject of Research: Tumor-selective protein degradation therapy using glutathione-activated Pro-LYTAC for triple-negative breast cancer.

Article Title: “Caged Glycan-Antibody Conjugates for Tumor-Selective Activation of Lysosome-Targeting Chimeras”

Web References: https://doi.org/10.1021/acs.jmedchem.6c01778

References: Journal of Medicinal Chemistry, DOI: 10.1021/acs.jmedchem.6c01778

Keywords

Pro-LYTAC, lysosome-targeting chimera, targeted protein degradation, cancer therapy, triple-negative breast cancer, glutathione, tumor microenvironment, immune evasion, glycan-antibody conjugate, tumor-selective treatment

Initial in vivo investigations into the biodistribution and maximum tolerated dose (MTD) of ErbB-OSV were conducted in immunodeficient NSG mice and benchmarked against VSV-ON-∆M51. Using a red-shifted NanoLuc reporter to monitor viral replication, ErbB-OSV consistently showed lower replication levels in non-tumor-bearing mice at comparable doses. This finding aligns with prior in vitro observations that this engineered virus has attenuated activity in normal cells, underscoring its enhanced selectivity for oncogenic cells. Notably, while VSV-ON-∆M51 precipitated rapid weight loss and mortality at doses of 3 × 10^9 or 10^10 TCID_50, ErbB-OSV was well tolerated at 3 × 10^9 TCID_50. This marked increase in tolerability translated into an MTD for ErbB-OSV at least threefold higher than that of VSV-ON-∆M51 in these immunocompromised models.

An enduring concern with RNA viruses as therapeutic agents is their propensity for higher mutation rates, which could jeopardize stability and safety. Addressing this, the investigators subjected both VSV-ON-∆M51 and ErbB-OSV to serial passaging in SKOV3 ovarian cancer cells and performed deep genomic sequencing analyses at multiple passage intervals. The mutation frequencies and distribution patterns were remarkably similar between the two viral populations, indicating that the modifications introduced into ErbB-OSV do not augment its intrinsic mutation rate. Importantly, while minor mutations accumulated over passages, no substantial genomic rearrangements or changes conferring a replication advantage emerged. The two most prevalent mutations in ErbB-OSV were synonymous changes in the nucleocapsid (N) gene, remaining stable without evidence of dominance. Clinically, this genomic stability resonates with the established safety record of VSV-based vaccines, such as those for Ebola, which have undergone extensive testing without problematic viral reversion or pathogenicity.

Crucially, the researchers embarked on a direct comparative assessment of ErbB-OSV and VSV-ON-∆M51’s antitumour efficacy against metastatic peritoneal ovarian cancer. NSG mice implanted intraperitoneally with pErbB-positive SKOV3 cells expressing firefly luciferase were treated weekly with either 10^9 TCID_50 of VSV-ON-∆M51 (at its MTD) or the same dose of ErbB-OSV, which is submaximal relative to its MTD. Bioluminescent imaging facilitated longitudinal tracking of tumour burden and viral distribution using distinct luciferase substrates for tumour and viral reporters.

These rigorous in vivo evaluations revealed compelling advantages for ErbB-OSV. At this submaximal dosing, ErbB-OSV significantly inhibited tumour progression relative to mock treatment, whereas VSV-ON-∆M51 failed to produce any measurable tumour suppression. Both viruses demonstrated active replication within the peritoneal cavity, confirming successful delivery. Moreover, ErbB-OSV-treated mice avoided the weight loss observed in controls, indicative of preserved health and reduced tumour burden. In contrast, VSV-ON-∆M51-treated mice showed no improvement in weight trajectories.

Survival analyses further accentuated the therapeutic benefits of ErbB-OSV. Although sample sizes were limited and cautious interpretation warranted, two out of five mice in the ErbB-OSV cohort displayed extended survival, one living over one year post tumour implantation, whereas VSV-ON-∆M51-treated mice exhibited no survival advantage. Necropsies corroborated imaging data: control and VSV-ON-∆M51 groups harbored numerous large tumour nodules along peritoneal surfaces, while ErbB-OSV-treated mice exhibited near complete absence of visible tumour masses.

Histopathology and immunofluorescence techniques provided additional insights into viral tropism. ErbB-OSV replication was highly tumor-specific, evidenced by robust expression of viral reporter genes within tumour sites but negligible activity in surrounding healthy organs. This tumour-restricted replication aligns with the virus’s molecular reprogramming to engage oncogenic ErbB signalling pathways selectively, thus sparing normal tissues from off-target cytotoxicity.

Synthesizing these findings, ErbB-OSV emerges as a safer and more potent oncolytic candidate than the extensively studied VSV-ON-∆M51. Its ability to achieve an MTD three times higher without adverse effects translates into enhanced dosing flexibility, while superior antitumour efficacy at submaximal doses signals improved therapeutic index. These attributes collectively underscore the promise of this engineered virus in advancing targeted virotherapies for metastatic ovarian cancer and potentially other ErbB-driven malignancies.

The implications of this research extend beyond ovarian cancer, demonstrating how rewiring viral tropism and replication pathways to harness oncogene dependencies enables precision ablation of metastatic tumours. By tailoring virus-host interactions to tumour-specific vulnerabilities, such synthetic viruses offer a paradigm shift from broad-spectrum cytotoxic agents to highly selective, self-amplifying therapies with intrinsic imaging and safety monitoring capabilities.

Future studies will undoubtedly probe combination strategies integrating ErbB-OSV with immune checkpoint inhibitors, chemotherapy, or radiotherapy to further enhance anti-malignant efficacy and durability of response. Additionally, assessments in immunocompetent models are essential to understand host immune interactions and potential vaccine-like systemic responses elicited by this open-shell virus.

In conclusion, this study marks a milestone in oncolytic virotherapy, demonstrating that multiplexed engineering of viral vectors targeting oncogenic signalling cascades can substantially improve therapeutic outcomes. ErbB-OSV exemplifies the successful convergence of virology, molecular oncology, and genetic engineering to create precision biologics capable of confronting metastatic disease with unprecedented efficacy and safety.

Subject of Research:

Article Title:

Article References:
Zou, X., Palafox, E., Zhao, C. et al. Rewiring oncogenic signalling to precision ablation of metastatic cancer. Nat. Biomed. Eng (2026). https://doi.org/10.1038/s41551-026-01704-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41551-026-01704-9

Cold plasma, often termed the fourth state of matter, consists of partially ionized gases containing reactive species such as ions, electrons, radicals, and ultraviolet photons. When this plasma interacts with water, it generates plasma-activated water (PAW) with a distinct composition of reactive oxygen and nitrogen species (RONS). These reactive species are well documented for their capacity to disrupt cancer cell metabolism, induce apoptosis, and inhibit tumor growth. This study focuses on utilizing PAW to target MCF7 breast cancer cells, which serve as a standardized model for hormone-responsive breast cancer research.

The experimental setup involved treating water with cold plasma generated under controlled atmospheric conditions, ensuring the consistent formation of RONS within the liquid phase. The resultant PAW exhibits prolonged stability of reactive species, allowing for systemic administration in murine models bearing MCF7 tumors. Unlike traditional chemotherapeutic agents that often cause systemic toxicity, PAW leverages the biochemical effects of oxidative stress to selectively compromise cancer cells, thus mitigating adverse side effects.

In the treated mice, administration of plasma-activated water led to significant tumor size reduction compared to control groups receiving non-activated water. Detailed histological analyses revealed increased apoptosis markers such as caspase-3 activation and DNA fragmentation within the tumor microenvironment. Furthermore, there was a discernible decrease in proliferative indices, corroborated by reduced Ki-67 staining. These cellular responses imply that PAW initiates programmed cell death pathways while halting cell proliferation, pointing to a multifaceted mode of action against breast cancer cells.

Mechanistically, the therapeutic efficacy of PAW appears to stem from the elevation of intracellular reactive oxygen species beyond the threshold of cancer cell tolerance. Cancer cells, which inherently exhibit altered redox homeostasis, are more susceptible to oxidative damage than normal cells. The exogenous ROS supplied via PAW impose oxidative stress that dysregulates mitochondrial membrane potential and triggers intrinsic apoptotic cascades. Additionally, reactive nitrogen species contribute to nitrosative damage, further amplifying cytotoxic effects.

Interestingly, the study also assessed the systemic toxicity of PAW treatment by monitoring vital organs such as liver, kidney, and spleen. Histopathological examination and serum biochemical assays showed negligible damage or inflammation in these organs, affirming the biocompatibility of treatment. This highlights the therapeutic window in which PAW exerts antitumor activity without sacrificing host viability—a critical parameter for translational applicability.

Another notable aspect is the modulation of the tumor microenvironment by PAW. Tumors rely heavily on neovascularization and an immune-suppressive milieu to sustain growth and metastasis. The researchers observed that PAW treatment negatively affected angiogenesis, as evidenced by downregulation of vascular endothelial growth factor (VEGF) expression within tumor tissues. Moreover, immune cell infiltration patterns shifted favorably, with increased presence of cytotoxic T lymphocytes indicative of an augmented antitumor immune response.

The versatility of cold plasma technology extends beyond water activation. Direct application of cold plasma onto cancer cells or tissues has been explored previously, but challenges regarding penetration depth and exposure uniformity limit its clinical use. PAW overcomes these hurdles by serving as a portable and injectable medium that retains plasma-derived reactive species, thus offering greater flexibility in delivery routes, including intravenous or intratumoral injections.

From a chemical standpoint, the composition of PAW is intricate, featuring a mixture of hydrogen peroxide, nitrites, nitrates, and other reactive intermediates in concentrations tuned by plasma parameters such as power, exposure time, and gas composition. Fine-tuning these parameters allows for optimization of PAW’s therapeutic potency, creating a customizable platform for different cancer types or treatment regimens. Furthermore, the stability of PAW under physiological conditions supports its development as an off-the-shelf therapeutic agent.

Despite its promise, several challenges remain before PAW can be adopted in clinical oncology. Long-term safety profiles need rigorous evaluation, especially regarding the potential for oxidative damage to non-target tissues in humans. The pharmacokinetic behavior of reactive species in vivo must be elucidated to guide dosing schedules. Additionally, understanding the interaction of PAW with conventional therapeutics such as chemotherapy, radiation, or immunotherapy could enable synergistic treatment strategies.

The findings by Abd El-Reda et al. open vistas for integrating plasma medicine into cancer management, aligning with the broader trend of harnessing physical sciences for biomedical innovation. Cold plasma-activated water represents a confluence of physics, chemistry, and biology, translating fundamental plasma phenomena into tangible medical interventions. Its minimally invasive nature paired with selective tumor cytotoxicity underscores the potential to reduce patient burden and improve quality of life.

As researchers continue to explore the underlying molecular pathways modulated by PAW, advanced models including patient-derived xenografts and clinical trials will be instrumental in validating efficacy and safety. In addition, technological advancements improving plasma generation units hold promise for scalable production which is essential for widespread clinical adoption.

In conclusion, cold plasma-activated water emerges as a powerful new modality in the fight against breast cancer, demonstrating targeted therapeutic effects in preclinical models. The ability to induce programmed cell death, modulate the tumor microenvironment, and stimulate immune responses points to its multifaceted antitumor capabilities. With continued research and development, this innovative approach could soon complement or even enhance existing cancer treatments, heralding a new era in oncology therapeutics predicated on plasma science.

The implications extend beyond breast cancer and may encompass various malignancies where oxidative stress can be tactically exploited. This study exemplifies the translational potential of cutting-edge physical technologies in medicine, potentially paving the way for novel, effective, and less toxic cancer therapies that enhance patient survival and well-being worldwide.

Subject of Research: Therapeutic application of cold plasma-activated water in treating MCF7 breast cancer tumors in mouse models.

Article Title: Therapeutic effects of cold plasma-activated water on MCF7 breast cancer tumors in a mouse model

Article References:
Abd El-Reda, G., Mahmoud, M.A.M., Ali, F.A.Z. et al. Therapeutic effects of cold plasma-activated water on MCF7 breast cancer tumors in a mouse model. BMC Pharmacol Toxicol (2026). https://doi.org/10.1186/s40360-026-01127-x

Image Credits: AI Generated

The challenge with many promising oncological drugs, especially those large in molecular size such as PROTACs, lies in their limited cellular uptake. Conventional delivery methods frequently fail to ferry these drugs past the robust protective membrane of cells, resulting in suboptimal efficacy and troubling side effects caused by off-target activity. SonoPIN addresses this by employing engineered microbubbles that can be selectively attached to malignant cells through synthetic nucleic acid strands customized to recognize unique biochemical markers present exclusively on cancerous cell membranes.

When these microbubbles are subjected to controlled ultrasound waves, they undergo a phenomenon called sonoporation. In this process, the microbubbles collapse violently, generating mechanical forces — including high-velocity microjets and localized shock waves — directed at the adjacent cancer cells. These forces puncture transient nanoscale pores within the cellular membrane, temporarily increasing permeability without causing lasting damage. The pores provide gateways allowing the typically impermeable PROTAC molecules to pass effortlessly into the intracellular environment where they exert their therapeutic effects.

The intricacies of sonoporation remain a topic of ongoing research, but the prevailing model emphasizes its gentle yet precise mechanical nature. Unlike indiscriminate cellular disruption, sonoporation encourages the temporary opening of cell membranes in a way that maintains cell viability beyond short exposure. Notably, cells naturally reseal these pores rapidly, typically within minutes, thus mitigating prolonged vulnerability and minimizing unintended toxicity to surrounding tissues.

In experimental benchtop studies, the Duke team meticulously calibrated the ultrasound frequencies and intensity parameters to maximize drug delivery efficiency. They validated the method’s specificity by conjugating fluorescent markers to the PROTACs, revealing a sevenfold increase in intracellular accumulation when administered via the SonoPIN platform compared to conventional approaches. Remarkably, this led to a dramatic therapeutic outcome wherein 50% of targeted cancer cells were induced to self-destruct—a process known as apoptosis—while 99% of non-targeted healthy cells remained unharmed.

PROTAC technology itself represents a revolutionary shift in drug discovery and cancer treatment paradigms. Unlike traditional inhibitors, PROTACs function as molecular matchmakers, binding simultaneously to disease-causing proteins and E3 ubiquitin ligase enzymes. This recruitment triggers ubiquitination, a cellular signal designating the bound proteins for degradation by proteasomes, the cell’s “garbage disposal” machinery. In cancer cells, targeting proteins such as BRD4, crucial for uncontrolled proliferation, effectively dismantles their survival mechanisms and halts tumor progression.

Despite their transformative potential, the therapeutic deployment of PROTACs has been hindered by poor cell permeability and systemic toxicity risks due to off-target effects. This is especially critical as proteins like BRD4 are also vital to normal cell function. The SonoPIN platform’s ability to direct PROTAC uptake exclusively within cancer cells addresses this fundamental obstacle, highlighting its immense promise for clinical translation.

Looking ahead, the research team aims to extend their work beyond cellular models into in vivo applications using mouse tumor models. They are currently exploring the feasibility of administering PROTACs and microbubbles intravenously while employing focused ultrasound to precisely target tumor sites. This localized delivery strategy, if successful, could revolutionize cancer treatment by amplifying drug potency, reducing systemic exposure and side effects, and broadening the spectrum of deliverable therapeutics.

Another exciting aspect of SonoPIN is its mechanistic reliance on physical rather than biological uptake pathways. This distinction suggests an overarching versatility to deliver a wide array of therapeutic agents beyond PROTACs, including large biomolecular assemblies like gene-editing complexes or antibodies, which are traditionally challenging to transport efficiently into cells. Such versatility could open new frontiers in precision medicine and personalized oncology.

The research was financially supported by prominent agencies, including the National Institutes of Health and the National Science Foundation, underscoring the high-impact nature and translational relevance of the study. The findings were published in the prestigious journal Proceedings of the National Academy of Sciences with extensive contributions from multidisciplinary experts spanning mechanical engineering, molecular biology, and pharmaceutical sciences.

This innovation stands as a testament to the power of interdisciplinary collaboration in tackling formidable challenges in cancer therapeutics. By harnessing the interplay between acoustics, nanotechnology, and molecular pharmacology, SonoPIN holds the potential to catapult drug delivery methodologies into a new era where precision, efficacy, and safety coexist harmoniously to benefit patients worldwide.

Subject of Research: Cells

Article Title: SonoPIN Enables Precise, Noninvasive, and Efficient Intracellular Delivery of PROTACs.

News Publication Date: 13-Mar-2026

Web References: DOI: 10.1073/pnas.2534439123

Image Credits: Duke University

Keywords: Cancer medication, Medical treatments, Cancer, Ultrasound, Drug delivery systems, Pharmaceuticals

The team’s focus was on the design and synthesis of a range of alepterolic acid derivatives, which cleverly incorporate indole and piperazine moieties. This strategic chemical manipulation enhances the bioactivity of these compounds, making them formidable contenders in the battle against breast cancer. The indole and piperazine additives are particularly noteworthy, as they are known to exhibit a wide range of biological activities, which could lead to more efficacious cancer treatments. By enhancing the pharmacological profile of alepterolic acid, the research addresses a pressing need for more effective chemotherapy options.

Breast cancer remains one of the leading causes of cancer-related deaths, emphasizing the urgency for novel therapeutic strategies. The research conducted by Ma et al. not only targets the cancer cells more effectively but also aims to understand the underlying mechanisms through which these newly synthesized compounds operate. By elucidating the mechanisms of action, the study creates a pathway that aids in the rational design of future anticancer agents. This systematic approach ensures that the compounds developed are optimized for both efficacy and safety.

In vitro studies revealed that certain derivatives displayed remarkable cytotoxicity against breast cancer cell lines. This highlights the potential for these compounds to induce apoptosis, a process that selectively destroys cancerous cells while leaving normal cells relatively unscathed. The specificity of these new agents offers a paradigm shift in oncology, as it addresses the critical balance between therapeutic efficacy and the preservation of healthy tissue.

To further understand the impact of the newly synthesized compounds, the research team engaged in rigorous mechanistic evaluation. Through a series of cellular and molecular assays, they identified critical pathways involved in the cytotoxic effects of these derivatives. The interplay between signaling pathways provides insights into how these innovative agents can disrupt cancer cell proliferation and survival. This aspect of the research is vital for the continued development of targeted therapies that not only inhibit tumor growth but also mitigate the chances of resistance.

Moreover, the compounds’ pharmacokinetic profiles were assessed, providing essential data on their absorption, distribution, metabolism, and excretion. Optimization of these characteristics is crucial for successful translation from bench to bedside. By prioritizing compounds with favorable pharmacokinetics, the researchers increase the likelihood of successful clinical applications, ultimately enhancing patient outcomes in breast cancer treatment.

Collaboration across disciplines was a cornerstone of the study, bringing together chemists, biologists, and pharmacologists. This interdisciplinary approach fosters innovation, allowing for the efficient synthesis and evaluation of new drug candidates. Such teamwork is vital in the fast-paced realm of drug discovery, where the convergence of skillsets can lead to groundbreaking advancements in cancer therapy.

The promising results of this research pave the way for further investigation into the safety and efficacy of these alepterolic acid derivatives in vivo. Future studies will focus on animal models, aiming to establish proof of concept before progressing to human clinical trials. This transition from laboratory research to clinical application is a monumental step that requires meticulous planning and execution to ensure patient safety and efficacy.

As we delve deeper into the molecular intricacies of cancer, the potential of small-molecule therapies like the ones developed in this study cannot be overstated. The incorporation of indole and piperazine structures not only enhances the biological activity but also provides a template for the future design of anticancer agents. The versatility of these small molecules opens new doors for the treatment of various cancer types, expanding the breadth of therapeutic options available to oncologists.

The implications of this research extend beyond breast cancer treatment. The knowledge gained from understanding the mechanism of action can be applied to other cancers, broadening the scope of impact. Researchers are optimistic that the successful development of these compounds could signify the dawn of a new generation of anticancer drugs, tailored to disrupt the unique biological landscape of different malignancies.

The dedication of the researchers involved in this study embodies the spirit of scientific inquiry and innovation. Their commitment to addressing one of the most pressing health challenges of our time reflects a determination to improve lives. With continued investment in research and development, the goal of creating more effective and targeted cancer therapies is becoming increasingly attainable.

In conclusion, the promising findings surrounding alepterolic acid derivatives represent a pivotal moment in cancer research. As scientists unlock the potential of these compounds, the hope for improved breast cancer treatments becomes more tangible. The meticulous design, synthesis, and evaluation of these novel agents stand as a testament to the power of science in the fight against cancer, igniting optimism for the future of cancer therapy.

Subject of Research: New anticancer agents derived from alepterolic acid targeting breast cancer.

Article Title: Design, synthesis, and mechanistic evaluation of alepterolic acid derivatives incorporating indole and piperazine moieties as anticancer agents targeting breast cancer.

Article References: Ma, L., Sun, Y., Zhang, B. et al. Design, synthesis, and mechanistic evaluation of alepterolic acid derivatives incorporating indole and piperazine moieties as anticancer agents targeting breast cancer. Mol Divers (2025). https://doi.org/10.1007/s11030-025-11406-0

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11030-025-11406-0

Keywords: alepterolic acid, indole, piperazine, breast cancer, anticancer agents, drug design, cancer therapy, apoptosis, pharmacokinetics, molecular mechanisms.

The core innovation lies in the development and application of SnOx nanoflakes synthesized through the electrochemical oxidation of tin disulfide (SnS2) powders. These two-dimensional nanostructures possess exceptional photothermal conversion capabilities, meaning they efficiently absorb near-infrared light and convert it into localized heat. When exposed to LED-generated near-infrared illumination, these nanoflakes become activated, generating enough thermal energy to induce targeted cancer cell death without harming nearby healthy cells. This selectivity is crucial in minimizing collateral damage, a pervasive issue in many current cancer treatments.

Traditional photothermal therapy typically relies on laser sources to direct intense light toward cancerous areas. While effective, lasers are expensive, require specialized and often immobile equipment, and risk damaging surrounding healthy tissues due to their high energy intensity. The substitution of lasers with LEDs in this new approach addresses these limitations directly. LEDs are widely available, cheaper, and can be engineered into compact, portable devices. This transition could democratize access to advanced cancer treatment technologies, especially in underserved regions where hospital-based specialized equipment is scarce.

In vitro experiments have produced compelling evidence supporting the efficacy and safety of this combined LED and SnOx nanoflake therapy. When cultured skin and colorectal cancer cells were exposed to near-infrared LED light in the presence of these nanoflakes, the system achieved up to 92% destruction of skin cancer cells and 50% eradication of colorectal cancer cells within just 30 minutes of treatment. Crucially, these results were obtained without observable detrimental effects on healthy human skin cells, highlighting the treatment’s precision and biocompatibility.

This technology harnesses the principles of near-infrared photothermal therapy, which exploits the tissue-penetrative properties of near-infrared light to deliver heat specifically to malignant cells. As these cancer cells absorb the light-activated heat produced by the SnOx nanoflakes, their local temperature rises to levels sufficient to induce apoptosis or necrosis. Because the therapy operates at relatively low light intensities and employs a biocompatible nanoparticle agent, it promises a gentler alternative to invasive surgical procedures or the systemic toxicity that accompanies many chemotherapeutic regimens.

The successful collaboration between researchers at UT Austin and the University of Porto is bolstered by the UT Austin Portugal Program, a long-standing bilateral scientific partnership bridging U.S. and Portuguese institutions. This program facilitated the transatlantic exchange of expertise, resources, and ideas that enabled the convergence of electrical engineering, materials science, and biomedical research inherent in this project. The synergistic efforts have yielded not only mechanistic insights but also practical prototypes, including custom-designed, near-infrared LED heating systems tailored to activate the SnOx nanoflakes efficiently.

Looking forward, the research team has set ambitious objectives to deepen understanding of the photothermal and photonic interactions governing the therapy’s effectiveness. Further investigation will explore alternative catalytic nanomaterial candidates that may offer enhanced efficacy or novel functional properties. Additionally, device engineering is a critical next step, focusing on developing user-friendly, portable platforms capable of delivering this therapy in clinical and even home-based settings, particularly for skin cancer patients.

One envisioned application is a wearable, lightweight device that a patient could place directly on the skin post-surgery to irradiate the surgical site and eradicate residual cancerous cells. Such an approach could significantly reduce recurrence rates and alleviate patients from repeated hospital visits. Moreover, the anticipated low-cost nature of the technology could facilitate adoption in low-resource environments worldwide, addressing long-standing disparities in cancer treatment accessibility.

The therapeutic use of SnOx nanoflakes also exemplifies the frontier of two-dimensional material science in biomedical applications. The nanoscale morphology and high surface area of these flakes enhance their interaction with near-infrared light and maximize thermal conversion. This precision targeting at the cellular level optimizes therapeutic outcomes while minimizing systemic side effects. The team continues to optimize the synthesis and functionalization of these nanomaterials, tailoring their physicochemical properties to improve stability, biocompatibility, and treatment efficacy.

An additional exciting outcome of this multidisciplinary venture is the recent procurement of supplementary funding aimed at developing an implantable device for breast cancer patients. This implant would integrate the photothermal capabilities of SnOx nanoflakes with minimally invasive delivery methods, representing an advanced step in personalized cancer therapy. It underscores the broad potential of this research beyond topical or external applications, opening avenues for treatment of diverse cancer types.

Besides the principal investigators, the research effort encompasses a diverse team of scientists and engineers. Their collective expertise spans electrical engineering, nanomaterial synthesis, biological characterization, and device engineering, epitomizing a modern collaborative approach to translational research. Notably, the development of the LED systems was spearheaded by contributors from the University of Trás-os-Montes and Alto Douro, showcasing a wide-reaching network of academic partnerships within Portugal.

This novel therapeutic approach is a landmark in photothermal cancer therapies, promising to surmount critical barriers hampering previous iterations of the technology. By leveraging more affordable and accessible LED technology alongside advanced nanomaterials, the method holds promise not only for improving patient outcomes but also for fundamentally reshaping cancer treatment modalities worldwide. Its evolution from laboratory discovery through clinical device development may transform how cancer is managed globally, combining cutting-edge science with practical healthcare delivery.

The fusion of material science, optical engineering, and oncology demonstrated in this work exemplifies the forward trajectory of cancer research. As this method progresses towards clinical trials and broader implementation, the scientific and medical communities will be closely watching its impact. With continued innovation, this LED-activated SnOx nanoflake therapy could inaugurate a new era of cancer treatment—one defined by precision, safety, accessibility, and hope for millions of patients worldwide.

Subject of Research: Cancer treatment using near-infrared photothermal therapy with SnOx nanoflakes activated by LED light.

Article Title: SnOx Nanoflakes as Enhanced Near-Infrared Photothermal Therapy Agents Synthesized from Electrochemically Oxidized SnS2 Powders

Web References:
https://doi.org/10.1021/acsnano.5c03135

References: ACS Nano, peer-reviewed journal article reporting experimental results and material synthesis details.

Image Credits: The University of Texas at Austin

Keywords: cancer, skin cancer, colorectal cancer, cancer cells, cancer research, cancer treatments

The innovative therapeutic approach employs an adeno-associated virus (AAV), a benign vector sophisticatedly engineered to infiltrate only KSHV-infected cancer cells. The selectivity exploits a unique viral protein, LANA, which is exclusively expressed in cells harboring this oncogenic herpesvirus. Upon infection, the therapy activates, manufacturing a modified thymidine kinase enzyme within these compromised cells. This enzyme then metabolizes ganciclovir—an antiviral drug traditionally used against herpesviruses—transforming it into a potent cytotoxic agent that triggers the destruction of the infected cancer cells. This precision-guided mechanism resembles a molecular Trojan horse, siphoning the virus’s own biology to instruct self-destruction selectively within malignancies.

Lead researcher Professor Yoshihiro Izumiya and his team carried out extensive preclinical assessments employing both human cell cultures and murine models emulating KSHV-related tumors. Their studies demonstrated that tumors subjected to this gene therapy, in tandem with ganciclovir administration, exhibited dramatic growth arrest and regression, affirming the approach’s therapeutic efficacy. Intriguingly, the treatment was devoid of detectable adverse effects in the animal models, underscoring a safety profile that surpasses many existing anticancer regimens where systemic toxicity remains a formidable hurdle. This aspect accentuates the therapy’s translational potential for immunocompromised and vulnerable populations.

At the molecular level, the mechanism’s elegance lies in its reliance on LANA—a latency-associated nuclear antigen integral to KSHV’s lifecycle and oncogenic persistence. Since LANA is absent in uninfected cells, the gene therapy’s activation is confined, ensuring that non-malignant tissue is spared. This refined specificity counters the broad cytotoxicity induced by chemotherapy and radiation, signaling a transformative step towards precision oncology. Moreover, the system’s modular design suggests that similar strategies could be tailored for other virus-driven cancers, expanding the therapeutic arsenal against virally induced tumors.

The research also delved into synergistic treatment methodologies. The team observed that certain anticancer agents capable of reactivating latent KSHV enhanced the gene therapy’s efficacy by amplifying the expression of viral markers like LANA. This reactivation strategy effectively increases the therapeutic vector’s activation window, allowing a more robust penetration and elimination of the infected cancer cells. Such combinatorial regimens may optimize clinical outcomes and reduce the likelihood of resistance development.

Kaposi’s sarcoma, historically a devastating diagnosis with limited treatment options, particularly in resource-poor settings, stands to benefit immensely from these findings. Conventional treatments often entail systemic chemotherapy with substantial side effect profiles and variable efficacy, especially in patients with compromised immunity. The gene therapy’s precision and low toxicity offer a promising alternative that can extend survival and improve quality of life without the burden of debilitating side effects.

Notably, KSHV is implicated not just in Kaposi’s sarcoma but also in several rare yet aggressive lymphomas, including primary effusion lymphoma and multicentric Castleman disease. These cancers are notoriously difficult to treat due to their complex pathogenesis and the patients’ immunological vulnerabilities. The selective gene therapy approach unveiled by UC Davis scientists may pave a new path in tackling these malignancies by eradicating the viral reservoirs sustaining tumor growth.

Despite these promising preclinical results, the researchers emphasize that human trials remain further down the developmental pipeline. Rigorous investigations into dosage optimization, delivery methods, long-term safety, and efficacy are necessary before clinical implementation. However, the compelling nature of the results fuels optimism for a near future where personalization of cancer therapy—especially for virally induced cancers—becomes mainstream.

This trailblazing study opens doors to harnessing the viral biology of oncogenic viruses as therapeutic vulnerabilities. By redirecting the virus’s molecular machinery against itself, the therapy exemplifies a paradigm shift from nonspecific cytotoxic treatments to smart, virus-tailored interventions. The use of adeno-associated viruses as delivery vehicles further exemplifies the remarkable potential of gene therapy platforms in the fight against cancer.

The implications of this research transcend the immediate scope of KSHV-related cancers. It highlights how understanding the intricate virus-host dynamics can be translated into clinical innovations. As researchers continue to dissect the genomic and proteomic signatures unique to virus-associated tumors, therapies akin to this approach could revolutionize oncological precision medicine, reducing morbidity and reshaping the therapeutic landscape.

Underpinning this breakthrough are the meticulous efforts by Professor Izumiya’s interdisciplinary team at the UC Davis Department of Biochemistry and Molecular Medicine and the Department of Dermatology. Their collaborative work, funded by the National Cancer Institute and the American Cancer Society, underscores the critical importance of sustained investment in fundamental and translational research to combat cancer’s evolving challenges.

The findings, detailed in the upcoming December issue of Molecular Therapy Oncology, mark a substantial leap forward. They beckon a future where cancer treatment is not only guided by the tumor’s genetic makeup but also by the infectious agents that drive oncogenesis. This dual-faceted approach promises to transform clinical care paradigms for some of the most challenging cancers worldwide.

For patients, clinicians, and researchers alike, this gene therapy represents a beacon of hope—a therapeutic innovation marrying viral biology intricacy with cutting-edge gene editing technologies. Its successful transition from laboratory models to clinical settings could usher in a new era of personalized, effective, and safe treatment modalities against KSHV-associated malignancies and beyond.

Subject of Research: Gene Therapy for Kaposi’s Sarcoma-Associated Herpesvirus (KSHV)-Associated Cancers

Article Title: Design, development, and evaluation of gene therapeutics specific to KSHV-associated diseases

News Publication Date: 18-Dec-2025

Web References:

• UC Davis Comprehensive Cancer Center: https://health.ucdavis.edu/cancer/
• Kaposi’s Sarcoma Information: https://www.cancer.org/cancer/types/kaposi-sarcoma/about/what-is-kaposi-sarcoma.html
• Molecular Therapy Oncology Journal: https://www.cell.com/molecular-therapy-family/oncology/home
• Full Research Article: https://www.cell.com/molecular-therapy-family/oncology/fulltext/S2950-3299(25)00119-5

References:
Izumiya, Y., et al. (2025). Design, development, and evaluation of gene therapeutics specific to KSHV-associated diseases. Molecular Therapy Oncology, [DOI: 10.1016/j.omton.2025.201050].

Keywords:
Kaposi’s Sarcoma, KSHV, Gene Therapy, Adeno-Associated Virus, Thymidine Kinase, Ganciclovir, Viral Oncology, Precision Medicine, Cancer Therapeutics, Latent Viral Infection, Immunocompromised Patients, Targeted Cancer Therapy